Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02369874
Registration number
NCT02369874
Ethics application status
Date submitted
18/02/2015
Date registered
24/02/2015
Date last updated
10/02/2021
Titles & IDs
Public title
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Query!
Scientific title
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Query!
Secondary ID [1]
0
0
D4193C00002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EAGLE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Cancer
0
0
0
0
Query!
Head and neck
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - MEDI4736
Treatment: Drugs - MEDI4736 + Tremelimumab
Treatment: Drugs - Standard of Care
Experimental: MEDI4736 - MEDI4736 monotherapy
Experimental: MEDI4736 + Tremelimumab - MEDI4736 + tremelimumab combination therapy
Active Comparator: Standard of Care - Standard of Care
Treatment: Drugs: MEDI4736
MEDI4736 Monotherapy
Treatment: Drugs: MEDI4736 + Tremelimumab
MEDI4736 + Tremelimumab combination therapy
Treatment: Drugs: Standard of Care
Standard of Care
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as the time from the date of randomization until death due to any cause. OS was analyzed for the full analysis set, regardless of programmed death-ligand 1 (PD-L1) status.
Query!
Timepoint [1]
0
0
September 2015 to September 2018 (36 months)
Query!
Secondary outcome [1]
0
0
Overall Survival (OS) in PD-L1 Negative Participants
Query!
Assessment method [1]
0
0
OS is defined as the time from the date of randomization until death due to any cause. PD-L1 negative was defined as <25% of tumor cells with membrane staining for PD-L1 at any intensity.
Query!
Timepoint [1]
0
0
September 2015 to September 2018 (36 months)
Query!
Secondary outcome [2]
0
0
Overall Survival (OS) in PD-L1 Positive Participants
Query!
Assessment method [2]
0
0
OS is defined as the time from the date of randomization until death due to any cause. PD-L1 positive was defined as =25% of tumor cells with membrane staining for PD-L1 at any intensity.
Query!
Timepoint [2]
0
0
September 2015 to September 2018 (36 months)
Query!
Secondary outcome [3]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [3]
0
0
PFS was defined as the time from the date of randomization until the date of objective disease progression or death based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). Objective disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Query!
Timepoint [3]
0
0
September 2015 to September 2018 (36 months)
Query!
Secondary outcome [4]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [4]
0
0
The percentage of participants who experienced an objective response (complete response [CR] or partial response [PR]), based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to <10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.
Query!
Timepoint [4]
0
0
Assessed at randomization and every 8 weeks thereafter
Query!
Secondary outcome [5]
0
0
Duration of Response (DoR)
Query!
Assessment method [5]
0
0
Median DoR, in months, based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A complete response was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to <10 mm. A partial response was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.
Query!
Timepoint [5]
0
0
September 2015 to September 2018 (36 months)
Query!
Secondary outcome [6]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [6]
0
0
6 Months: The percentage of participants who had a best objective response of complete response (CR) or partial response (PR) in the first 6 months or had demonstrated stable disease (SD) for a minimum interval of 24 weeks following randomization.
12 Months: The percentage of participants who had a best objective response of CR or PR within 12 months or had demonstrated SD for a minimum interval of 48 weeks following randomization.
Objective response was based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to <10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.
Query!
Timepoint [6]
0
0
Baseline up to 6 months; baseline up to 12 months
Query!
Secondary outcome [7]
0
0
Percentage of Participants Alive and Progression Free (APF)
Query!
Assessment method [7]
0
0
APF is defined as the percentage of participants who are alive and progression free at 6 months and 12 months after randomization. Estimates of progression free survival were based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). Objective disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Query!
Timepoint [7]
0
0
Baseline up to 6 months; baseline up to 12 months
Query!
Secondary outcome [8]
0
0
Percentage of Participants Alive
Query!
Assessment method [8]
0
0
Percentage of participants alive at 12, 18 and 24 months using a Kaplan Meier estimate.
Query!
Timepoint [8]
0
0
12, 18 and 24 months
Query!
Secondary outcome [9]
0
0
Progression Free Survival (PFS) in PD-L1 Negative Participants
Query!
Assessment method [9]
0
0
Number of participants with confirmed objective disease progression (PD) at the time of the participant's last evaluable response evaluation criteria in solid tumors 1.1 (RECIST1.1) assessment. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD-L1 negative was defined as <25% of tumor cells with membrane staining for PD-L1 at any intensity.
Query!
Timepoint [9]
0
0
September 2015 to September 2018 (36 months)
Query!
Secondary outcome [10]
0
0
Objective Response Rate (ORR) in PD-L1 Negative Participants
Query!
Assessment method [10]
0
0
The percentage of PD-L1 negative participants who experienced an objective response (complete response [CR] or partial response [PR]), based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to <10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters. PD-L1 negative was defined as <25% of tumor cells with membrane staining for PD-L1 at any intensity.
Query!
Timepoint [10]
0
0
September 2015 to September 2018 (36 months)
Query!
Secondary outcome [11]
0
0
Time to Deterioration in European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire, Version 3 (EORTC QLQ-C30)
Query!
Assessment method [11]
0
0
The EORTC QLQ-C30 consists of 30 questions that can be combined to produce functional scales (e.g. physical), symptom scales (e.g. fatigue), and a global measure of health status. Each of the scales are measured from 0 to 100. Deterioration was defined as a 10-point decrease from baseline in a functioning or global health status/ quality of life score or a 10-point increase from baseline in a symptom score.
Query!
Timepoint [11]
0
0
September 2015 to September 2018 (36 months)
Query!
Secondary outcome [12]
0
0
Time to Deterioration for European Organisation for Research and Treatment of Cancer 35-item Head and Neck Quality of Life Questionnaire (EORTC QLQ-H&N35)
Query!
Assessment method [12]
0
0
The EORTC QLQ-H&N35 comprises of 35 questions to assess head and neck cancer symptoms (e.g. pain, swallowing). Deterioration was defined as a 10-point increase from baseline in the symptom score.
Query!
Timepoint [12]
0
0
September 2015 to September 2018 (36 months)
Query!
Secondary outcome [13]
0
0
Number of Participants Reporting One or More Adverse Events (AE)
Query!
Assessment method [13]
0
0
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Inclusive of AEs and serious AEs.
Query!
Timepoint [13]
0
0
First dose to last dose + 90 days or data cut off (up to 36 months)
Query!
Eligibility
Key inclusion criteria
- Age =18 years; - Written informed consent obtained from the
patient/legal representative; - Histologically or cytologically confirmed recurrent or
metastatic SCCHN; - Tumor progression or recurrence during or after only one palliative
systemic treatment regimen for recurrent or metastatic disease that must have contained a
platinum agent OR progression within 6 months of the last dose of platinum given as part of
multimodality therapy with curative intent; - Confirmed PD-L1-positive or -negative SCCHN
by the Ventana PD-L1 SP263 IHC assay; - WHO/Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1; At least 1 measurable lesion, - Not previously irradiated; -
No prior exposure to immune-mediated therapy; - Adequate organ and marrow function;
Evidence of post-menopausal status or negative urinary or serum pregnancy test for female
pre-menopausal patients.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
96
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Histologically or cytologically confirmed
squamous cell carcinoma of any other primary anatomic location in the head and neck; -
Received more than 1 palliative systemic regimen for recurrent or metastatic disease; -Any
concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy for cancer
treatment; - Receipt of any investigational anticancer therapy within 28 days or 5
half-lives; - Receipt of last dose of an approved (marketed) anticancer therapy
(chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the
first dose of study treatment; - Major surgical procedure within 28 days prior to the first
dose of Investigational Product; - Any unresolved toxicity NCI CTCAE Grade =2 from previous
anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values
defined in the inclusion criterion; - Current or prior use of immunosuppressive medication
within 14 days before the first dose of their assigned Investigational Product; - History
of allogeneic organ transplantation; - Active or prior documented autoimmune or
inflammatory disorders; - Uncontrolled intercurrent illness; - Patients with a history of
brain metastases, spinal cord compression, or leptomeningeal carcinomatosis; - Mean QT
interval corrected for heart rate (QTc) =470 ms calculated from 3 electrocardiograms (ECGs)
using Fridericia's Correction; - History of active primary immunodeficiency; - Active
tuberculosis; - Active infection including hepatitis B, hepatitis C or human
immunodeficiency virus (HIV); - Receipt of live, attenuated vaccine within 30 days prior to
the first dose of Investigational Product; - Pregnant or breast-feeding female patients; -
Known allergy or hypersensitivity to Investigational Product
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/09/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
13/11/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
736
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Adelaide
Query!
Recruitment hospital [2]
0
0
Research Site - Heidelberg
Query!
Recruitment hospital [3]
0
0
Research Site - Melbourne
Query!
Recruitment hospital [4]
0
0
Research Site - St Leonards
Query!
Recruitment hospital [5]
0
0
Research Site - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [3]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [5]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Delaware
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Virginia
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Caba
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
San Miguel de Tucuman
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Brussels
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Bruxelles
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Charleroi
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Kortrijk
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Leuven
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Namur
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Barretos
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Curitiba
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Porto Alegre
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Rio de Janeiro
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Santo Andre
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
São José do Rio Preto
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
São Paulo
Query!
Country [31]
0
0
Bulgaria
Query!
State/province [31]
0
0
Shumen
Query!
Country [32]
0
0
Bulgaria
Query!
State/province [32]
0
0
Sofia
Query!
Country [33]
0
0
Bulgaria
Query!
State/province [33]
0
0
Varna
Query!
Country [34]
0
0
Chile
Query!
State/province [34]
0
0
Temuco
Query!
Country [35]
0
0
Croatia
Query!
State/province [35]
0
0
Osijek
Query!
Country [36]
0
0
Croatia
Query!
State/province [36]
0
0
Zagreb
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Olomouc
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Zlin
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Angers
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Bordeaux
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Dijon
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Le Mans
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Lyon Cedex 08
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Montpellier Cedex 5
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Paris Cedex 5
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Plerin SUR MER
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Rouen
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
St Grégoire
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Strasbourg Cedex
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Villejuif Cedex
Query!
Country [51]
0
0
Georgia
Query!
State/province [51]
0
0
Lorient Cedex
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Berlin
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Essen
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Halle
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Hannover
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Heidelberg
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Leipzig
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
München
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Potsdam
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Budapest
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Gyor
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Kecskemét
Query!
Country [63]
0
0
Israel
Query!
State/province [63]
0
0
Haifa
Query!
Country [64]
0
0
Israel
Query!
State/province [64]
0
0
Jerusalem
Query!
Country [65]
0
0
Israel
Query!
State/province [65]
0
0
Petach-Tikva
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Tel Aviv
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Tel Hashomer
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Aosta
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Bologna
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Gallarate
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Legnago
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Milano
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Napoli
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Pavia
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Roma
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Siena
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Chuo-ku
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Fukuoka-shi
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Hirakata-shi
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Isehara-shi
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Kashiwa
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Kitaadachi-gun
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Kobe-shi
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Koto-ku
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Matsuyama-shi
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Nagoya
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Natori-shi
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Okayama
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Osakasayama
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Osaka
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Sapporo
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Shimotsuke-shi
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Sunto-gun
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Takatsuki-shi
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Yokohama-shi
Query!
Country [96]
0
0
Japan
Query!
State/province [96]
0
0
Yokohama
Query!
Country [97]
0
0
Korea, Republic of
Query!
State/province [97]
0
0
Daegu
Query!
Country [98]
0
0
Korea, Republic of
Query!
State/province [98]
0
0
Goyang-si
Query!
Country [99]
0
0
Korea, Republic of
Query!
State/province [99]
0
0
Seoul
Query!
Country [100]
0
0
Korea, Republic of
Query!
State/province [100]
0
0
Suwon
Query!
Country [101]
0
0
Poland
Query!
State/province [101]
0
0
Kraków
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Poznan
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Lódz
Query!
Country [104]
0
0
Romania
Query!
State/province [104]
0
0
Baia Mare
Query!
Country [105]
0
0
Romania
Query!
State/province [105]
0
0
Brasov
Query!
Country [106]
0
0
Romania
Query!
State/province [106]
0
0
Cluj-Napoca
Query!
Country [107]
0
0
Romania
Query!
State/province [107]
0
0
Cluj
Query!
Country [108]
0
0
Romania
Query!
State/province [108]
0
0
Craiova
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
Arkhangelsk
Query!
Country [110]
0
0
Russian Federation
Query!
State/province [110]
0
0
Chelyabinsk
Query!
Country [111]
0
0
Russian Federation
Query!
State/province [111]
0
0
Kursk
Query!
Country [112]
0
0
Russian Federation
Query!
State/province [112]
0
0
Moscow
Query!
Country [113]
0
0
Russian Federation
Query!
State/province [113]
0
0
Nizhniy Novgorod
Query!
Country [114]
0
0
Russian Federation
Query!
State/province [114]
0
0
Omsk
Query!
Country [115]
0
0
Russian Federation
Query!
State/province [115]
0
0
Pyatigorsk
Query!
Country [116]
0
0
Russian Federation
Query!
State/province [116]
0
0
Saint Petersburg
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
Saint-Petersburg
Query!
Country [118]
0
0
Russian Federation
Query!
State/province [118]
0
0
Sankt-Peterburg
Query!
Country [119]
0
0
Russian Federation
Query!
State/province [119]
0
0
Sochi
Query!
Country [120]
0
0
Russian Federation
Query!
State/province [120]
0
0
Ufa
Query!
Country [121]
0
0
Russian Federation
Query!
State/province [121]
0
0
Vladimir
Query!
Country [122]
0
0
Serbia
Query!
State/province [122]
0
0
Belgrade
Query!
Country [123]
0
0
Serbia
Query!
State/province [123]
0
0
Belgrad
Query!
Country [124]
0
0
Serbia
Query!
State/province [124]
0
0
Kragujevac
Query!
Country [125]
0
0
Serbia
Query!
State/province [125]
0
0
Nis
Query!
Country [126]
0
0
Serbia
Query!
State/province [126]
0
0
Sremska Kamenica
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Barcelona
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
L'Hospitalet de Llobregat
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
Madrid
Query!
Country [130]
0
0
Spain
Query!
State/province [130]
0
0
Malaga
Query!
Country [131]
0
0
Spain
Query!
State/province [131]
0
0
Marbella
Query!
Country [132]
0
0
Spain
Query!
State/province [132]
0
0
Pamplona
Query!
Country [133]
0
0
Spain
Query!
State/province [133]
0
0
Valencia
Query!
Country [134]
0
0
Spain
Query!
State/province [134]
0
0
Zaragoza
Query!
Country [135]
0
0
Taiwan
Query!
State/province [135]
0
0
Kaohsiung
Query!
Country [136]
0
0
Taiwan
Query!
State/province [136]
0
0
Taipei
Query!
Country [137]
0
0
Taiwan
Query!
State/province [137]
0
0
Taoynan
Query!
Country [138]
0
0
Ukraine
Query!
State/province [138]
0
0
Dnipro
Query!
Country [139]
0
0
Ukraine
Query!
State/province [139]
0
0
Kyiv
Query!
Country [140]
0
0
Ukraine
Query!
State/province [140]
0
0
Sumy
Query!
Country [141]
0
0
Ukraine
Query!
State/province [141]
0
0
Uzhhorod
Query!
Country [142]
0
0
Ukraine
Query!
State/province [142]
0
0
Zaporizhzhia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a randomized, open-label, multi-center, global, Phase III study to determine the
efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy
versus SoC therapy in the target patient population.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02369874
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Nassim Morsli, MD
Query!
Address
0
0
Medical Director AstraZeneca
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02369874
Download to PDF